Skip to main content
SpringerLink
Log in
Book cover

Neutron Capture Therapy pp 117–160Cite as

Drugs for BNCT: BSH and BPA

  • Chapter
  • First Online:

Abstract

This chapter is based on a shortened version of the investigators brochures from the EORTC clinical trials 11001 and 11011 concerning the boron compounds sodium borocaptate (BSH) and boronophenylalanine (BPA). It summarizes essential information that might be asked by regulatory authorities. The intention of this chapter is to support and to facilitate the preparation of new clinical trials based on these compounds. However, this compilation cannot offer a complete and final description of all aspects concerning these 2 compounds necessary to file for drug approval.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Gabel D, Sauerwein W (1995) Approaching clinical trials of boron neutron capture therapy in Europe. In: Kogelnik HD (ed) Progress in radio-oncology V. Monduzzi Editore, Bologna, pp 315–319

    Google Scholar 

  2. Sauerwein W, Hideghéty K, Gabel D, Moss R (1998) European clinical trials of boron neutron capture therapy for glioblastoma. Nuclear News 41:54–56

    Google Scholar 

  3. Sauerwein W, Moss R, Rassow J, Stecher-Rasmussen F, Hideghéty K, Wolbers JG, Sack H (1999) Organisation and management of the first clinical trial of BNCT in Europe (EORTC Protocol 11961). Strahlenther Onkol 175:108–111

    Article  PubMed  Google Scholar 

  4. Hideghéty K, Sauerwein W, Haselsberger K, Grochulla F, Fankhauser H, Moss R, Huiskamp R, Gabel D, de Vries M (1999) Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation facility (EORTC Protocol 11961). Strahlenther Onkol 175:111–114

    Article  PubMed  Google Scholar 

  5. Pignol JP, Paquis P, Breteau N, Chauvel P, Sauerwein W, EORTC BNCT Study Group (1999) Boron neutron capture enhancement of fast neutron for nonremoved glioblastomas: rationale of a clinical trial. Front Radiat Ther Oncol 33:43–50

    Article  PubMed  CAS  Google Scholar 

  6. Hideghéty K, Moss R, Sauerwein W, EORTC BNCT Study Group (2000) Controversies in establishment of dose limiting qualitative and quantitative toxicity for radiation modality. Radiother Oncol 57:S7–S9

    Article  Google Scholar 

  7. Hüsing J, Sauerwein W, Hideghéty K, Jöckel K-H (2001) A scheme for a dose-escalation study when the event is lagged. Stat Med 20:3323–3334

    Article  PubMed  Google Scholar 

  8. Sauerwein W, Hideghéty K, Rassow J, Moss RL, Stecher-Rasmussen F, Heimans J, Gabel D, de Vries MJ, Touw DJ, the EORTC BNCT Study Group (2001) Boron neutron capture therapy: an interdisciplinary cooperation. In: IAEA-TECDOC-1223 “Current status of neutron capture therapy”, International Atomic Energy Agency, Vienna, 2001, pp 96–107

    Google Scholar 

  9. Sauerwein W, Hideghéty K, Rassow J, de Vries MJ, Götz C, Paquis P, Grochulla F, Wolbers JG, Haselsberger K, Turowski B, Moss RL, Stecher-Rasmussen F, Touw D, Wiestler OD, Fankhauser H, Gabel D, the EORTC BNCT Study Group (2001) First clinical results from the EORTC phase I trial “Postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility”. In: IAEA-TECDOC-1223 “Current status of neutron capture therapy”, International Atomic Energy Agency, Vienna, 2001, pp 250–256

    Google Scholar 

  10. Michel J, Sauerwein W, Wittig A, Balossier G, Zierold K (2002) Boron localisation in cells by electron energy loss spectroscopy. In: Sauerwein W, Moss R, Wittig A (eds) Research and development in neutron capture therapy. Monduzzi Editore, Bologna, pp 925–928

    Google Scholar 

  11. Sauerwein W, Zurlo A, on behalf of the EORTC Boron Neutron Capture Therapy Group (2002) The EORTC Boron Neutron Capture Therapy (BNCT) Group: achievements and future projects. EJC 38:S31–S34

    Article  Google Scholar 

  12. Hideghéty K, Sauerwein W, Wittig A, Götz C, Paquis P, Grochulla F, Haselsberger K, Wolbers J, Moss R, Huiskamp R, Fankhauser H, de Vries M, Gabel D (2003) Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. J Neurooncol 62:145–156

    PubMed  Google Scholar 

  13. van Rij CM, Wilhelm AJ, Sauerwein WAG, van Loenen AC (2005) Boron neutron capture therapy for glioblastoma multiforme. Pharm World Sci 27:92–95

    Article  PubMed  CAS  Google Scholar 

  14. Mauri PL, Basilico F, Wittig A, Heimans J, Huiskamp R, Sauerwein W (2006) Pharmacokinetics and metabolites of 10B-containing compounds in biological fluids. In: Nakagawa Y, Kobayashi T, Fukuda H (eds) Advances in neutron capture therapy 2006. International Society for Neutron Capture Therapy and Neutrino OSAKA Inc, Osaka, pp 271–273. ISBN 4-990342-0-X

    Google Scholar 

  15. Wittig A, Malago M, Collette L, Huiskamp R, Bührmann S, Nievaart V, Kaiser GM, Jöckel KH, Schmid KW, Ortmann U, Sauerwein W (2008) Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC trial 11001). Int J Cancer 122:1164–1171

    Article  PubMed  CAS  Google Scholar 

  16. Wittig A, Collette L, Moss R, Sauerwein WA (2009) Early clinical trial concept for boron neutron capture therapy: a critical assessment of the EORTC trial 11001. Appl Radiat Isot 67:S59–S62

    Article  PubMed  CAS  Google Scholar 

  17. Wittig A, Collette L, Appelman K, Bührmann S, Jäckel MC, Jöckel KH, Schmid KW, Ortmann U, Moss R, Sauerwein WA (2009) EORTC trial 11001: distribution of two (10)B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. J Cell Mol Med 13:1653–1665

    Article  PubMed  Google Scholar 

  18. Bendel P, Wittig A, Basilico F, Mauri P, Sauerwein W (2010) Metabolism of Borono-phenylalanine-fructose complex (BPA-fr) and Borocaptate Sodium (BSH) in cancer patients – results from EORTC trial 11001. J Pharm Biomed Anal 51:284–287

    Article  PubMed  CAS  Google Scholar 

  19. Soloway AH, Hatanaka H, Davis M (1967) Penetration of brain and brain tumor. VII. Tumor binding sulfhydryl compounds. J Med Chem 10:714–717

    Article  PubMed  CAS  Google Scholar 

  20. Hatanaka H (1975) A revised boron-neutron capture therapy for malignant brain tumors. II. Interim clinical result with the patients excluding previous treatments. J Neurol 209:81–94

    Article  PubMed  CAS  Google Scholar 

  21. Gabel D, Sauerwein W (1994) Clinical implementation of boron neutron capture therapy in Europe. In: Amaldi U, Larsson B (eds) Hadrontherapy in oncology. Elsevier Science, Amsterdam, pp 509–517

    Google Scholar 

  22. Gabel D, Preusse D, Haritz D, Grochulla F, Haselsberger K, Fankhauser H, Ceberg C, Peters HD, Klotz U (1997) Pharmacokinetics of Na2B12H11 SH (BSH) in patients with malignant brain tumours as a prerequisite for a phase I clinical trial of boron neutron capture. Acta Neurochir (Wien) 139:606–612

    Article  CAS  Google Scholar 

  23. Gibson CR, Staubus AE, Barth RF, Yang W, Ferketich AK, Moeschberger MM (2003) Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy. J Neurooncol 62(1–2):157–169

    PubMed  Google Scholar 

  24. Goodman JH, Yang W, Barth RF et al (2000) Boron neutron capture therapy of brain tumors: biodistribution, pharmacokinetics, and radiation dosimetry sodium borocaptate in patients with gliomas. Neurosurgery 47:608–621

    PubMed  CAS  Google Scholar 

  25. Hideghety K, Sauerwein W, Wittig A, Götz C, Paquis P, Grochulla F, Haselsberger K, Wolbers J, Moss R, Huiskamp R, Fankhauser H, De Vries M, Gabel D (2003) Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. J Neurooncol 62:145–156

    PubMed  Google Scholar 

  26. Wittig A, Malago M, Collette L, Huiskamp R, Bührmann S, Nievaart V, Kaiser GM, Jöckel K, Kw S, Ortmann U, Sauerwein W (2008) Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC trial 11001). Int J Cancer 122:1164–1171

    Article  PubMed  CAS  Google Scholar 

  27. Wittig A, Huiskamp R, Moss RL, Bet P, Kriegeskotte C, Scherag A, Hilken G, Sauerwein WAG (2009) Biodistribution of 10B for Boron Neutron Capture Therapy (BNCT) in a Mouse Model after Injection of Sodium Mercaptoundecahydro-closo-dodecaborate and L-para-Boronophenylalanine. Radiat Res 172:493–499

    Article  PubMed  CAS  Google Scholar 

  28. Wittig A, Stecher-Rasmussen F, Hilger RA, Rassow J, Mauri P, Sauerwein W (2011) Sodium mercaptoundecahydro-closo-dodecaborate (BSH), a boron carrier that merits more attention. Appl Radiat Isot. doi:10.1016/j.apradiso.2011.02.046

  29. Peters HD, Gabel D (1997) Treatment of glioma with boron neutron capture therapy with Na2B12H11SH – compilation of literature data on toxicity and pharmacokinetics in animals. Summary of the European phase I toxicity and pharmacokinetics study. European Collaboration on Boron Neutron Capture Therapy: 1–47

    Google Scholar 

  30. Wittig A, Michel J, Moss RL, Stecher-Rasmussen F, Arlinghaus HF, Bendel P, Mauri P, Altieri S, Hilger R, Salvadori PA, Menichetti L, Zamenhof R, Sauerwein WAG (2008) Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT). Crit Rev Oncol Hematol 68:66–90

    Article  PubMed  Google Scholar 

  31. Haselsberger K, Radner H et al (1994) Subcellular boron-10 localization in glioblastoma for boron neutron capture therapy with Na2B12H11SH. J Neurosurg 81:741–744

    Article  PubMed  CAS  Google Scholar 

  32. Clendenon NR, Barth RF, Gordon WA et al (1990) Boron neutron capture therapy of a rat glioma. Neurosurgery 26:47–55

    Article  PubMed  CAS  Google Scholar 

  33. Gabel D, Holstein H, Larsson B et al (1987) Quantitative neutron capture radiography for studying the biodistribution of tumor-seeking boron-containing compounds. Cancer Res 47:5451–5454

    PubMed  CAS  Google Scholar 

  34. Joel DD, Slatkin DN, Micca PL, Nawrocky MMD, Velez C (1989) Uptake of boron into human gliomas of athymic mice and into syngeneic cerebral gliomas of rats after intra carotid infusion of sulfhydryl boranes. In: Fairchild RG, Bond VP, Woodhead AD (eds) Clinical aspects of neutron capture therapy. Plenum Press, New York, pp 325–332

    Google Scholar 

  35. Joel DD, Slatkin DN, Micca PL, Nawrocky MM, Dubois T, Velez C (1989) Uptake of boron into human gliomas of athymic mice and into syngeneic cerebral gliomas of rats after intracarotid infusion of sulfhydryl boranes. Basic Life Sci 50:325–332

    PubMed  CAS  Google Scholar 

  36. Joel D, Slatkin D, Fairchild R, Micca P, Nawrocky M (1989) Pharmacokinetics and tissue distribution of the TI – sulfhydryl boranes (monomer and dimer) in glioma-bearing rats. Strahlenther Onkol 165:167–170

    PubMed  CAS  Google Scholar 

  37. Joel D, Slatkin D, Coderre J (1993) Uptake of 1OB in gliosarcoma :following the injection of glutathione monoethyl ester and sulfhydryl borane. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in neutron capture therapy. Plenum Press, New York, pp 501–504

    Chapter  Google Scholar 

  38. Wittig A, Arlinghaus H, Kriegeskotte C, Moss R, Appelman K, Schmid K, Sauerwein W (2008) Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs. Mol Cancer Ther 7:1763–1771

    Article  PubMed  CAS  Google Scholar 

  39. Hatanaka H (1997) Boron neutron capture therapy for tumors. Nishimura, Niigata

    Google Scholar 

  40. Harfst S, Moller D, Ketz H, Roesler J (1994) Reversed-phase separation of ionic organoborate clusters by high-performance liquid chromatography. J Chromatogr A 678:41

    Article  CAS  Google Scholar 

  41. LaHann TR, Daniell G (1997) Death following single dose administration of borocaptate sodium. In: Larsson B, Crawford I, Weinreich R (eds) Chemistry and biology, vol II. Elsevier Science, Amsterdam, pp 175–180

    Google Scholar 

  42. Morris GM, Constantine G, Ross G, Yeung TK, Hopewell JW (1993) Boron neutron capture therapy long term effects on the skin and spinal cord of the rat. Radiat Res 135:330–386

    Google Scholar 

  43. Horn V, Buchar E, Janku I (1997) Kidney function changes in rats after single-dose administration of borocaptate sodium. Physiol Res 46:279–283

    PubMed  CAS  Google Scholar 

  44. Gavin PR, DeHaan CE, Kraft SL, Moore MP, Wendling LR, Dorn RV (1994) Large animal normal tissue tolerance with boron neutron capture. Int J Radiat Oncol Biol Phys 28(5):1099–1106

    Article  PubMed  CAS  Google Scholar 

  45. Gavin PR, Kraft SL, Wendling LR, Miller DL (1989) Canine spontaneous brain tumors – a large animal model for BNCT. Strahlenther Onkol 165(2/3):225–228

    PubMed  CAS  Google Scholar 

  46. Gavin PR, Kraft SL, Huiskamp R, Coderre JA (1997) A review: CNS effects and normal tissue tolerance in dogs. J Neurooncol 33(1–2):71–80

    Article  PubMed  CAS  Google Scholar 

  47. Janku I, Buchar E, Jiricka Z (1993) Nephrotoxicity of borocaptate after short-term administration in rabbits. Toxicology 79:99–108

    Article  PubMed  CAS  Google Scholar 

  48. Kinashi Y, Masunaga S-I, Ono K (2002) Mutagenic effect of borocaptate sodium and borophenylalanine in neutron capture therapy. Int J Radiat Oncol Biol Phys 54:562–567

    Article  PubMed  CAS  Google Scholar 

  49. Sweet WH, Messer JR, Hatanaka H (1986) Supplementary pharmacological study between 1972 and 1977 on purified mercaptoundecahydrododecaborate. In: Hatanaka H (ed) Boron neutron capture therapy for tumors. Nishimura, Niigata, pp 59–76

    Google Scholar 

  50. Morris GM, Coderre JA, Hopewell JW, Micca PL, Rezvani M (1994) Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. Radiother Oncol 32:144–153

    Article  PubMed  CAS  Google Scholar 

  51. Kraft SL, Gavin PR, Leathers CW, DeHaan CE, Bauer WF, Miller DL, Dorn RV, Griebenow ML (1994) Biodistribution of boron in dogs with spontaneous intracranial tumors following borocaptate sodium administration. Cancer Res 54(5):1259–1263

    PubMed  CAS  Google Scholar 

  52. Yamaguchi T, Nakajima Y, Miyamoto H, Mizobuchi M, Kanazu T, Kadono K, Nakamoto K, Ikeuchi I (1998) Distribution and excretion of boron after intravenous administration of disodium mercaptoundecahydro-closo-dodecaborate to rats. J Toxicol Sci 23:577–585

    Article  PubMed  CAS  Google Scholar 

  53. Mehta SC, Lu DR (1995) Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharm Drug Dispos 16:735–744

    Article  PubMed  CAS  Google Scholar 

  54. Nakagawa T, Nagai T (1976) Interaction between albumin and mercaptoundecahydrododecaborate ion (an agent for boron neutron capture therapy of brain tumour). Chem Pharm Bull 24:2934–2954

    Article  PubMed  CAS  Google Scholar 

  55. Bauer WF, Bradshaw KM, Richards TL (1992) Interaction between boron containing compounds and serum albumin observed by nuclear magnetic resonance. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in neutron capture therapy for cancer. Plenum Press, New York, pp 339–344

    Chapter  Google Scholar 

  56. Samsel EG, Miller DL (1989) High resolution 10B and 11B nuclear magnetic resonance (NMR) spectroscopy of Na2B12H11SH impurities and metabolites. Strahlenther Onkol 165:140

    PubMed  CAS  Google Scholar 

  57. Bradshaw KM, Schweizer M, Glover G, Hadley J (1993) Pharmacokinetics of borocaptate sodium in canine head determined by 11B. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in neutron capture therapy. Plenum Press, New York, pp 579–583

    Chapter  Google Scholar 

  58. Tang PP, Schweizer MP, Bradshaw KM, Bauer WF (1995) 11B nuclear magnetic resonance studies of the interaction of borocaptate sodium with serum albumin. Biochem Pharmacol 49:625–632

    Article  PubMed  CAS  Google Scholar 

  59. Kawabata S, Miyatake S, Nonoguchi N, Hiramatsu R, Iida K, Miyata S, Yokoyama K, Doi A, Kuroda Y, Kuroiwa T, Michiue H, Kumada H, Kirihata M, Imahori Y, Maruhashi A, Sakurai Y, Suzuki M, Masunaga S, Ono K (2009) Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot 67:15–18

    Article  CAS  Google Scholar 

  60. Matsuda M, Yamamoto T, Kumada H, Nakai K, Shirakawa M, Tsurubuchi T, Matsumura A (2009) Dose distribution and clinical response of glioblastoma treated with boron neutron capture therapy. Appl Radiat Isot 67:S19–S21

    Article  PubMed  CAS  Google Scholar 

  61. Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y (2004) Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61:1069–1073

    Article  PubMed  CAS  Google Scholar 

  62. Pöller F, Wittig A, Sauerwein W (1998) Calculation of boron neutron capture cell inactivation in vitro based on particle track structure and x-ray sensitivity. Radiat Environ Biophys 37:117–123

    Article  PubMed  Google Scholar 

  63. Amano K (1986) Boron-10-mercaptoundecahydrododecaborate distribution in human brain tumors as studied by neutron-induced alpha-autoradiography. In: Hatanaka H (ed) Boron neutron capture therapy for tumors. Nishimura, Niigata, pp 112–115

    Google Scholar 

  64. Otersen B, Haritz D, Grochulla F, Bergrnann M, Sierralta W, Gabel D (1996) Binding and immunohistochemical localization of Na2B12HI11SH to tumor tissue of gliorna patients in boron neutron capture therapy. In: Mishima Y (ed) Neutron capture therapy for human cancers. Plenum Press, New York, pp 627–633

    Google Scholar 

  65. Kageji T, Nakagawa Y, Kitamura K, Matsumoto K, Hatanaka H (1997) Pharmacokinetics and boron uptake of BSH (Na2B12H11SH) in patients with intracranial tumors. J Neurooncol 33:117–130

    Article  PubMed  CAS  Google Scholar 

  66. Ceberg CP, Persson A, Brun A et al (1995) Performance of BSH in patients with astrocytoma grades III-IV – a basis for boron neutron capture therapy. J Neurosurg 83:79–85

    Article  PubMed  CAS  Google Scholar 

  67. Haselsberger K, Radner H, Gössler W, Schlagenhaufen C, Pendl G (1994) Subcellular boron-10 localization in glioblastoma for boron neutron capture therapy with Na2B12H11SH. J Neurosurg 81:741–744

    Article  PubMed  CAS  Google Scholar 

  68. Thellier M, Chevallier A, His I, Jarvis MC, Lovell MA, Ripoll C, Robertson D, Sauerwein W, Verdus MC (2001) Methodological developments for application to the study of physiological boron and to boron neutron capture therapy. J Trace Microprobe Tech 19:623–657

    Article  CAS  Google Scholar 

  69. Wittig A, Wiemann M, Fartmann M, Kriegeskotte C, Arlinghaus HF, Zierold K, Sauerwein W (2005) Preparation of cells cultured on silicon wafers for mass spectrometry analysis. Microsc Res Tech 66:248–258

    Article  PubMed  CAS  Google Scholar 

  70. Michel J, Balossier G, Wittig A, Sauerwein W, Zierold K (2005) EELS spectrum-imaging for boron detection in biological cryofixed tissues. Instrum Sci Technol 33:631–644

    Article  CAS  Google Scholar 

  71. Michel J, Sauerwein W, Wittig A, Balossier G, Zierold K (2003) Subcellular localization of sodium borocaptate in cultured melanoma cells by electron energy-loss spectroscopy of freeze-dried cryosections. J Microsc 210:25–34

    Article  PubMed  CAS  Google Scholar 

  72. Haritz D, Gabel D, Klein H, Huiskamp R, Pettersson OK (1992) BSH in patients with malignant glioma: distribution in tissues, comparison between BSH concentration and histology. In: Gabel D, Moss RL (eds) Boron neutron capture therapy, toward clinical trials of glioma treatment. Plenum Press, New York, pp 103–174

    Google Scholar 

  73. Haritz D, Gabel D, Klein H, Piscol K (1992) Clinical investigations boron neutron capture therapy (BNCT). Pharmacokinetics, biodistribution, and toxicity of Na2B12H11 SH (BSH) in patients with malignant glioma. Adv Neurosurg 21:247–252

    Article  Google Scholar 

  74. Haritz D, Gabel D, Huiskamp R (1994) Clinical phase-I-study of Na2B12H11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). Int J Radiat Oncol Biol Phys 28:1175–1181

    Article  PubMed  CAS  Google Scholar 

  75. Haselsberger K, Radner H, Pendl G (1994) Boron neutron capture therapy: boron biodistribution and pharmacokinetics of Na-2B-12H-11SH in patients with glioblastoma. Cancer Res 54:6318–6320

    PubMed  CAS  Google Scholar 

  76. Haselsberger K, Radner H, Gössler W, Schagenhaufen C, Pendl G (1994) Subcellular boron-10 localization in glioblastoma for boron neutron capture therapy with Na2B12H11SH. J Neurosurg 81:741–744

    Article  PubMed  CAS  Google Scholar 

  77. Fankhauser H, Stragliotto G, Zbinden P (1992) Borocaptate sodium (BSH) pharmacokinetic in glioma patients. In: Gabel D, Moss RL (eds) Boron neutron capture therapy toward clinical trials of glioma treatment. Plenum Press, New York, pp 155–1644

    Google Scholar 

  78. Stragliotto O, Schüpbach D, Gavin P, Fankhauser H (1993) Update on biodistribution of borocaptate sodium (BSH) in patients with intracranial tumors. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in neutron capture therapy. Plenum Press, New York, pp 719–726

    Chapter  Google Scholar 

  79. Stragliotto G, Fankhauser H (1992) Biodistribution of boron sulfhydryl (BSH) in patients with intracranial tumors. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in neutron capture therapy for cancer. Plenum Press, New York, pp 551–556

    Chapter  Google Scholar 

  80. Stragliotto G, Fankhauser H, Gavin P, Meuli R (1993) Correlation of BSH uptake with CT scan contrast enhancement in patients with intracranial tumors. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in neutron capture therapy. Plenum Press, New York, pp 715–717

    Chapter  Google Scholar 

  81. Stragliotto G, Fankhauser H (1995) Biodistribution and pharmacokinetics of boron-sulfhydryl for boron neutron capture therapy in patients with intracranial tumors. Neurosurgery 36:285–293

    Article  PubMed  CAS  Google Scholar 

  82. Horn V, Slansky J, Janku I, Strouf O, Sourek K, Tovarys F (1998) Disposition and tissue distribution of boron after infusion of borocaptate sodium in patients with malignant brain tumors. Int J Radiat Oncol Biol Phys 41:631–638

    Article  PubMed  CAS  Google Scholar 

  83. Paquis P, Hideghety K, Wittig A et al (2002) Tissue uptake if BSH in patients with glioblastomas in the EORTC 11961 phase I trial. In: Sauerwein W, Moss RL, Wittig A (eds) Research and development in neutron capture therapy. Monduzii Editore S.p.A, Bologna, pp 1017–1022

    Google Scholar 

  84. Gibson CR, Staubus AE, Barth RF et al. Pharmacokinetics of sodium borocaptate, based on boron concentrations, after intravenous administration to glioma patients and simulations to optimize dosing for neutron capture therapy. J Pharmacokin Biopharm 2000

    Google Scholar 

  85. Kageji T, Nagahiro S, Kitamura K, Nakagawa Y, Hatanaka H, Haritz D, Grochulla F, Haselsberger K, Gabel D (2001) Optimal timing of neutron irradiation for boron neutron ­capture therapy after intravenous infusion of sodium borocaptate in patients with glioblastoma. Int J Radiat Oncol Biol Phys 51:120–130

    Article  PubMed  CAS  Google Scholar 

  86. Sauerwein W, Hilger RA, Appelman K, Moss R, Heimans J, Bet P, Wittig A (2008) Pharmacokinetics of BSH – results from EORTC trials. In: Zonta A, Altieri S, Roveda L, Barth R (eds) Neutron capture therapy: a new option against cancer. ENEA (Italian National Agency for New Technologies, Energy and the Environment), Florence, pp 58–61. ISBN 8-8286-176-8

    Google Scholar 

  87. Mauri PL, Basilico F, Pietta PG, Pasini E, Monti D, Sauerwein W (2003) New approach for the analysis of BSH and its metabolites using capillary electrophoresis and ESI-MS. J Chromatogr 788:9–16

    Article  CAS  Google Scholar 

  88. Basilico F, Sauerwein W, Pozzi F, Wittig A, Moss R, Mauri PL (2005) Analysis of 10B ­antitumoral compounds by means of flow-injection into ESI-MS/MS. J Mass Spectrom 40:1546–1549

    Article  PubMed  CAS  Google Scholar 

  89. Wittig A, Hideghety K, Paquis P et al (2002) Current clinical results of the EORTC-study 11961. In: Sauerwein W, Moss RL, Wittig A (eds) Research and development in neuron ­capture therapy, Essen (Germany). Monduzzi Editore S.p.A, Bologna, pp 1117–1121

    Google Scholar 

  90. Haselsberger K, Radner H et al (1998) Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase. Cancer Lett 131(1):109–111

    Article  PubMed  CAS  Google Scholar 

  91. Haritz D, Gabel D, Klein H, Huiskamp R (1993) Results of continued clinical investigations of BSH in patients with malignant glioma. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in neutron capture therapy. Plenum Press, New York, pp 727–730

    Chapter  Google Scholar 

  92. Snyder HR, Reedy AJ, Lennarj WJ (1958) Synthesis of aromatic boronic acids. Aldehyde boronic acids and a boronic acid analog of tyrosine. J Am Chem Soc 80:835–838

    Article  CAS  Google Scholar 

  93. Coderre JA, Glass JD, Packer S, Micca P, Greenberg D (1990) Experimental boron neutron capture therapy for melanoma: systemic delivery of boron to melanotic and amelanotic ­melanoma. Pigment Cell Res 3:310–318

    Article  PubMed  CAS  Google Scholar 

  94. Coderre JA, Chanana AD, Joel DD, Elowitz EH, Micca PL, Nawrocky MM, Chadha M, Gebbers JO (1998) Biodistribution of boronophenylalanine in patients with glioblastoma ­multiforme: boron concentration correlates with tumor cellularity. Radiat Res 149:163–170

    Article  PubMed  CAS  Google Scholar 

  95. Coderre JA, Glass JD, Fairchild RG, Micca PL, Fand I, Joel DD (1990) Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than ­melanoma. Cancer Res 50:138–141

    PubMed  CAS  Google Scholar 

  96. Elowitz EH, Bergland RM, Coderre JA, Joel DD, Chadha M, Chanana AD (1998) Biodistribution of p-boronophenylalanine (BPA) in patients with glioblastoma multiforme for use in boron neutron capture therapy. Neurosurgery 42:463–469

    Article  PubMed  CAS  Google Scholar 

  97. Solares G, Zamenhof R, Saris S, Wazer D, Kerley S, Joyce M, Madoc-Jones H, Adelman L, Harling O (1992) Biodistribution and pharmacokinetics of p boronophenylalanine in C57BL/6 mice with GL261 intracerebral tumors, and survival following neutron capture therapy. In: Allen BJ, Harrington BV, Moore DE (eds) Progress in neutron capture therapy for cancer. Plenum Press, New York and London, pp 475–478. ISBN 0·306·44104·7

    Chapter  Google Scholar 

  98. Wittig A, Sauerwein WA, Coderre JA (2000) Mechanisms of transport of p boronophenylalanine through the cell membrane in vitro. Radiat Res 153:173–180

    Article  PubMed  CAS  Google Scholar 

  99. Dagrosa MA, Viaggi M, Kreimann E, Farias S, Garavaglia R, Agote M, Cabrini RL, Dadino JL, Juvenal GJ, Pisarev MA (2002) Selective uptake of p-boronophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy. Thyroid 12:7–12

    Article  PubMed  CAS  Google Scholar 

  100. Sauerwein W (2005) 10B-uptake in different tumors using the boron compounds BSH and BP. EORTC protocol 11001 Version 2.0. EORTC boron neutron capture therapy group. European Organization for Research and Treatment of Cancer, Bruxelles, 2005

    Google Scholar 

  101. Van Rij CM, Sinjewel A, Van Loenen AC, Sauerwein WAG, Wittig A, Kriz O, Wilhelm AJ (2005) Stability of 10B-L-boronophenylalanine-fructose injection. Am J Health Syst Pharm 62:2608–2610

    Article  PubMed  CAS  Google Scholar 

  102. Chanana AD (1998) Request for extension of shelf-life for BPA-fructose solutions for patient infusions. FDA report # 43,317. 15-6-1998

    Google Scholar 

  103. Belkhou R, Abbe J-C, Pham P, Jasner N, Sahel J, Dreyfus H, Moutaouakkil M, Massarelli R (1995) Uptake and metabolism of boronophenylalanine in human uveal melanoma cells in culture. Relevance to boron neutron capture therapy of cancer cells. Amino Acids (Vienna) 8:217–229

    Article  CAS  Google Scholar 

  104. Papaspyrou M, Feinendegen LE, Muller-Gartner HW (1994) Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 54:6311–6314

    PubMed  CAS  Google Scholar 

  105. Matalka KZ, Bailey MQ, Barth RF et al (1993) Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. Cancer Res 53:3308–3313

    PubMed  CAS  Google Scholar 

  106. Gregoire V, Huiskamp R, Verrijk R, Begg AC (1992) Comparative pharmacokinetics and distribution studies of boric acid, L-BPA and BSH in two murine tumour models. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in neutron capture therapy for cancer, vol S. Plenum Press, New York and London, pp 443–445. ISBN 0·306·44104·7

    Chapter  Google Scholar 

  107. Gregoire V, Begg AC, Huiskamp R, Verrijk R, Bartelink H (1993) Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. Radiother Oncol 27:46–54

    Article  PubMed  CAS  Google Scholar 

  108. Pignol JP, Oudart H, Chauvel P, Sauerwein W, Gabel D, Prevot G (1998) Selective delivery of 10B to soft tissue sarcoma using 10B-L-borophenylalanine for boron neutron capture therapy. Br J Radiol 71:320–323

    PubMed  CAS  Google Scholar 

  109. Morris GM, Coderre JA, Micca PL, Fisher CD, Capala J, Hopewell JW (1997) Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine. Br J Cancer 76:1623–1629

    Article  PubMed  CAS  Google Scholar 

  110. Joel DD, Coderre JA, Micca PL, Nawrocky MM (1999) Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. J Neurooncol 41:213–221

    Article  PubMed  CAS  Google Scholar 

  111. Kiger WS, Palmer MR, Riley KJ, Zamenhof RG, Busse PM (2001) A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. Radiat Res 155:611–618

    Article  PubMed  CAS  Google Scholar 

  112. Svantesson E, Capala J, Markides KE, Pettersson J (2002) Determination of boron-containing compounds in urine and blood plasma from boron neutron capture therapy patients. The importance of using coupled techniques. Anal Chem 74:5358–5363

    Article  PubMed  CAS  Google Scholar 

  113. Coderre JA, Gavin PR, Capala J, Ma R, Morris GM, Button TM, Aziz T, Peress NS (2000) Tolerance of the normal canine brain to epithermal neutron irradiation in the presence of p-boronophenylalanine. J Neurooncol 48:27–40

    Article  PubMed  CAS  Google Scholar 

  114. Taniyama K, Fujiwara H, Kuno T et al (1989) Acute and subacute toxicity of 10B-paraboronophenylalanine. Pigment Cell Res 2:291–296

    Article  PubMed  CAS  Google Scholar 

  115. Kulvik M, Vahatalo J, Buchar E et al (2003) Clinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymmetric pathway. Eur J Pharm Sci 8:155–163

    Article  CAS  Google Scholar 

  116. Wambersie A, Gahbauer RA, Whitmore G, Levin CV Dose and volume specification for reporting NCT: an ICRU-IAEA initiative. Current status of neutron capture therapy (International Atomic Energy Agency Report No. IAEA-TECDOC-1223, 2001), pp 9–10

    Google Scholar 

  117. Setiawan Y, Halliday GM, Harding AJ, Moore DE, Allen BJ (1995) Effect of L-10B-p-boronophenylalaninefructose and the boron neutron capture reaction on mouse brain ­dopaminergic neurons. Cancer Res 55:874–877

    PubMed  CAS  Google Scholar 

  118. Coderre JA, Morris GM, Kalef-Ezra J et al (1999) The effects of boron neutron capture irradiation on oral mucosa: evaluation using a rat tongue model. Radiat Res 152:113–118

    Article  PubMed  CAS  Google Scholar 

  119. Coderre JA, Kalef-Ezra JA, Fairchild RG, Micca PL, Reinstein LE, Glass JD (1988) Boron neutron capture therapy of a murine melanoma. Cancer Res 48:6313–6316

    PubMed  CAS  Google Scholar 

  120. Tamaoki N, Ueda M, Tamauchi S, Yamamoto K, Mishima Y (1989) Use of nude mice in experimental neutron capture therapy with 10B-BPA. Pigment Cell Res 2:343–344

    Article  PubMed  CAS  Google Scholar 

  121. Ono K, Masunaga S, Suzuki M, Kinashi Y, Takagaki M, Akaboshi M (1999) The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice. Int J Radiat Oncol Biol Phys 43:431

    Article  PubMed  CAS  Google Scholar 

  122. Barth RF, Yang W, Rotaru JH et al (1997) Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood–brain barrier disruption. Cancer Res 57:1129–1136

    PubMed  CAS  Google Scholar 

  123. Barth RF, Yang W, Bartus RT, Moeschberger ML, Goodman JH (1999) Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog cereport (receptor-mediated permeabilizer-7). Neurosurgery (Baltimore) 44:351–359

    Article  CAS  Google Scholar 

  124. Yang W, Barth RF, Bartus RT et al (2000) Improved survival after boron neutron capture therapy of brain tumors by cereport-mediated blood–brain barrier modulation to enhance delivery of boronophenylalanine [in process citation]. Neurosurgery 47:189–197

    PubMed  CAS  Google Scholar 

  125. Mallesch JL, Moore DE, Allen BJ, McCarthy WH, Jones R, Stening WA (1994) The ­pharmacokinetics of p-boronophenylalanine fructose in human patients with glioma and metastatic melanoma. Int J Radiat Oncol Biol Phys 28:1183–1188

    Article  PubMed  CAS  Google Scholar 

  126. Wittig A, Sheu-Grabellus S-Y, Collette L, Moss R, Brualla L, Sauerwein W (2011) BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot 69:1807–1812

    Article  PubMed  CAS  Google Scholar 

  127. Bergenheim AT, Capala J, Roslin M, Henriksson R (2005) Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol 71(3):287–293

    Article  PubMed  CAS  Google Scholar 

  128. Liberman SJ, Dagrosa A, Jimenez Rebagliati RA, Bonomi MR, Roth BM, Turjanski L, Castiglia SI, Gonzalez SJ, Menendez PR, Cabrini R, Roberti MJ, Batistoni DA (2004) Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl Radiat Isot 61(5):1095–1100

    Article  PubMed  CAS  Google Scholar 

  129. Fukuda H, Honda C, Wadabayashi N, Kobayashi T, Yoshino K, Hiratsuka J, Takahashi J, Akaizawa T, Abe Y, Ichihashi M, Mishima Y (1999) Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Melanoma Res 9(1):75–83

    Article  PubMed  CAS  Google Scholar 

  130. Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD (1998) Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 40(4):829–834

    Article  PubMed  CAS  Google Scholar 

  131. Zonta A, Prati U, Roveda L, Ferrari C, Valsecchi P, Trotta F, DeRoberto A, Rossella C, Bernardi G, Zonta C, Marchesi P, Pinelli T, Altieri S, Bruschi P, Fossati F, Barni S, Chiari P, Nano R (2000) La terapia per cattura neutronica (BNCT) dei tumori epatici. Boll Soc Med Chir 114(2):123–144

    Google Scholar 

  132. Altieri S, Bortolussi S, Bruschi P, Chiari P, Fossati F, Stella S, Prati U, Roveda L, Zonta A, Zonta C, Ferrari C, Clerici A, Nano R, Pinelli T (2008) Neutron autoradiography imaging of selective boron uptake in human metastatic tumours. Appl Radiat Isot 66(12):1850–1855

    Article  PubMed  CAS  Google Scholar 

  133. Cardoso J, Nievas S, Pereira M, Schwint A, Trivillin V, Pozzi E, Heber E, Monti Hughes A, Sanchez P, Bumaschny E, Itoiz M, Liberman S (2009) Boron biodistribution study in colorectal liver metastases patients in Argentina. Appl Radiat Isot 67(7–8 Suppl):S76–S79

    Article  PubMed  CAS  Google Scholar 

  134. Pisarev MA, Dagrosa MA, Juvenal GJ (2005) Application of boron neutron capture therapy to the treatment of anaplastic thyroid carcinoma: current status and future perspectives. Curr Opin Endocrinol Diabetes 12(5):352–355

    Article  Google Scholar 

  135. Wittig A, Sheu S-Y, Kaiser GM, Lang S, Jöckel K-H, Moss R, Stecher-Rasmussen F, Rassow J, Collette L, Sauerwein W (2008) New indications for BNCT? Results from the EORTC trial 11001. In: Zonta A, Altieri S, Roveda L, Barth R (eds) Neutron capture therapy: a new option against cancer. ENEA (Italian National Agency for New Technologies, Energy and the Environment), Florence, pp 39–42. ISBN 88-8286-167-8

    Google Scholar 

  136. Coderre JA (1992) A phase 1 biodistribution study of p-boronophenylalanine. In: Gabel D, Moss R (eds) Boron neutron capture therapy: towards clinical trials of glioma treatment. Plenum Press, New York, pp 111–121

    Google Scholar 

  137. Cruickshank GS, Ngoga D et al (2009) A cancer research UK pharmacokinetic study of ­BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. Appl Radiat Isot 67(7–8 Suppl):S31–S33

    Article  PubMed  CAS  Google Scholar 

  138. Ryynanen PM, Kortesniemi M, Coderre JA, Diaz AZ, Hiismaki P, Savolainen SE (2000) Models for estimation of the (10)B concentration after BPA-fructose complex infusion in patients during epithermal neutron irradiation in BNCT. Int J Radiat Oncol Biol Phys 48:1145–1154

    Article  PubMed  CAS  Google Scholar 

  139. Wittig A, Sauerwein W, Moss R, Stecher-Rasmussen F, Nivaart V, Grabbe S, Heimans J, Collette L, van Loenen A, Buehrmann S, Roca A, Hoving A, Rassow J (2006) Early phase II study on BNCT in metastatic malignant melanoma using the boron carrier BPA (EORTC protocol 11011). In: Nakagawa Y, Kobayashi T, Fukuda HE (eds) Advances in neutron capture therapy 2006. Proceedings of ICNCT-12 Y. International Society for Neutron Capture Therapy, Kagawa, 2006, pp 284–287

    Google Scholar 

  140. Mauri P, Basilico F, Wittig A, Heimans J, Huiskamp R, Sauerwein W (2006) Pharmacokinetics and metabolites of 10B-containing compounds in biological fluids. In: Nakagawa Y, Kobayashi T, Fukuda HE (eds) Advances in neutron capture therapy 2006. Proceedings of ICNCT-12. International Society for Neutron Capture Therapy, Kagawa, 2006, pp 271–273

    Google Scholar 

  141. Coderre JA, Morris GM, Kalef-Ezra J, Micca PL, Ma R, Youngs K, Gordon CR (1999) The effects of boron neutron capture irradiation on oral mucosa: evaluation using a rat tongue model. Radiat Res 152(2):113–118

    Article  PubMed  CAS  Google Scholar 

  142. Kiger WS 3rd, Micca PL, Morris GM, Coderre JA (2002) Boron microquantification in oral mucosa and skin following administration of a neutron capture therapy agent. Radiat Prot Dosimetry 99(1–4):409–412

    Article  PubMed  CAS  Google Scholar 

  143. Morris GM, Smith DR, Patel H, Chandra S, Morrison GH, Hopewell JW, Rezvani M, Micca PL, Coderre JA (2000) Boron microlocalization in oral mucosal tissue: implications for boron neutron capture therapy. Br J Cancer 82(11):1764–1771

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NCTeam, Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, D-45122, Essen, Germany

    Wolfgang A. G. Sauerwein

  2. Department of Clinical Pharmacology and Pharmacy, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

    Pierre M. Bet

  3. Department of Radiotherapy and Radiation Oncology, Philipps-University Marburg, Marburg, Germany

    Andrea Wittig

Authors
  1. Wolfgang A. G. Sauerwein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre M. Bet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Wittig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang A. G. Sauerwein .

Editor information

Editors and Affiliations

  1. Zentrum für Konservative Onkologie, Klinik für Strahlentherapie, Univ.Klinikum Essen, Hufelandstr. 55, Essen, 45122, Germany

    Wolfgang Sauerwein

  2. Philipps-University Marburg, Department of Radiation Oncology, University Hospital Marburg,, Baldingerstrasse 1, Marburg, 35043, Germany

    Andrea Wittig

  3. Joint Research Centre, Institute for Engergy, European Commission, Westerduinweg 3, LE Petten, 1755, Netherlands

    Raymond Moss

  4. , Department of Neurosurgery, Kagawa National Children's Hospital, Zentsuji-cho 2603, Zentsuji, 765-8501, Kagawa, Japan

    Yoshinobu Nakagawa

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Sauerwein, W.A.G., Bet, P.M., Wittig, A. (2012). Drugs for BNCT: BSH and BPA. In: Sauerwein, W., Wittig, A., Moss, R., Nakagawa, Y. (eds) Neutron Capture Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31334-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-31334-9_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-31333-2

  • Online ISBN: 978-3-642-31334-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation